

NCT ID	NCT06013111
Title	An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors
Phase	Phase 1
Date Added	2023-08-28
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05438342
Title	An Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis
Phase	Not Applicable
Date Added	2022-06-29
Location	China
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Chemotherapy?checkpoint immunotherapy, targeted therapy
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03692429
Title	alloSHRINK – Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
Phase	Phase 1
Date Added	2018-10-02
Location	Florida, United States Belgium
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	CYAD-101, FOLFIRI, FOLFOX
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03935893
Title	Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Phase	Phase 2
Date Added	2019-05-02
Location	Pennsylvania, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Fludarabine + Cyclophosphamide combination, Tumor Infiltrating Lymphocytes (TIL)
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03296137
Title	Adoptive Cell Therapy Across Cancer Diagnoses
Phase	Phase 1/Phase 2

Date Added	2017-09-28
Location	Denmark
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	Autologous tumor-infiltrating lymphocytes, Cyclophosphamide, Fludara, Ipilimumab, Nivolumab, proleukin, Opdivo, Yervoy
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT03412877
Title	Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Phase	Phase 2
Date Added	2018-01-29
Location	Maryland, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Aldesleukin, Cyclophosphamide, Fludarabine, Individual Patient TCR-Transduced PBL, Pembrolizumab (Keytruda)
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT03190941
Title	Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Phase	Phase 1, Phase 2
Date Added	2017-06-19
Location	Maryland, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Anti-KRAS G12V mTCR PBL, Cyclophosphamide, Fludarabine, High-dose Aldesleukin
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT03745326
Title	Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Phase	Phase 1, Phase 2
Date Added	2018-11-19
Location	Maryland, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Aldesleukin, anti-KRAS G12D mTCR PBL, Cyclophosphamide, Fludarabine
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT03280511
Title	Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients
Phase	Phase 2
Date Added	2017-09-12
Location	Denmark
Prior IO Allowed	Yes
CRC-directed	Yes

Status	Recruiting
Drugs	PIPAC
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT05382741
Title	Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial
Phase	Phase 2
Date Added	2022-05-19
Location	Italy
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Durvalumab Injection for intravenous use 500 mg vial solution for infusion, Regorafenib 30 mg capsules, Imfinzi, Stivarga
Tags	MSS/ MMRp